Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Summary

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

Timeline

Start

2008-10

Primary completion

2010-01

Completion

2010-01

Outcome

Met primary endpoint

registry analysis (unspecified test); All Treatments GLYC-101 Gel, 0.1% vs All Treatments Placebo; p = 0.0062; Wilcoxon (Mann-Whitney) NCT00792688 ↗

registry analysis (unspecified test); All Treatments GLYC-101 Gel, 1.0% vs All Treatments Placebo; p = 0.0331; Wilcoxon (Mann-Whitney) NCT00792688 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	beta-glucan	Other / unclassified	0.1 %	Topical
Subject	beta-glucan	Other / unclassified	1 %	Topical

Indications

No indication recorded.